Review of antiretroviral agents for the treatment of HIV infection

Formulary

Volumn 44, Issue 2, 2009, Pages 47-54

  Stanic, Anela ^a   Grana, Julie C ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ATAZANAVIR PLUS RITONAVIR; CHEMOKINE RECEPTOR ANTAGONIST; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GLYCOPROTEIN GP 120; INTEGRASE INHIBITOR; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR; VICRIVIROC; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ABNORMAL DREAMING; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EYE DISEASE; FATIGUE; GASTROINTESTINAL DISEASE; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; LIFE CYCLE; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; REVIEW; SINUS TACHYCARDIA; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS CAPSID; VIRUS INHIBITION; VIRUS LOAD; VOMITING;

EID: 77951861906     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS Epidemic Update: December 2007.
2. Celentano DD. Undocumented epidemics of HIV continue to persist in the twenty-first century. AIDS. 2005;19:527-528.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus (HIV) infection. N Engl J Med. 1998;338:853-860.
4. Levy JA. HIV pathogenesis and long-term survival. AIDS. 1993;7:1401-1410.
5. Alfano M, Poli G. The HIV life cycle: Multiple targets for antiretroviral agents. Drug Design Reviews-Online. 2004;1:83-92.
6. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-1367.
7. Correll T, Klibanov OM. Integrase inhibitors: A new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008;28:90-101.
8. Rana KZ, Dudley MN. Human immunodeficiency virus protease inhibitors. Pharmacotherapy. 1999;19:35-59.
9. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc vs efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. Program and abstracts of the 4th International AIDS Society conference on HI V pathogenesis, treatment and prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
10. Este J, Telenti A. HIV entry inhibitors. Lancet. 2007;370:81-88.
11. Selzentry [package insert]. New York, NY: Pfizer Labs; August 2007.
12. Gulick R, Su Z, Flexner C, et al, and the ACTG 5211 Team. ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48-week results. Presented at: Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUAB102.
13. Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects [erratum in: Antimicrobial Agents Chemother. 2007;51:3047].
14. Antimicrobial Agents Chemother. 2007;51:2351-2358.
15. Correll T, Klibanov OM. Integrase inhibitors: A new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008;28:90-101.
16. Markowitz M et al. Potent antiviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatmentnaive HIV-1 infected patients. Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0214.
17. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
18. Jones J, Taylor B, Wilkin TJ, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2007;15:48-82.
19. Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; January 2008.
20. Ripamonti D, Maggiolo F. Rilpivirine, a nonnucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Curr Opin Investig Drugs. 2008; 9:899-912.
21. Molina JM, Cordes C, Ive P, et al. Efficacy and safety of TMC278 in antiretroviral-naive, HIV-infected patients: week 96 data from TMC278-C204. Program and abstracts of the 9th International Congress on Drug Therapy in HIV Infection; November 9-13, 2008; Glasgow, United Kingdom. Abstract P002.
22. Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC), Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008; 1-146. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 23, 2009.
23. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS. 2004;18:259-273.
24. Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb; March 2008.
25. Rudorf DC, Krikorian SA. Adverse effects associated with antiretroviral therapy and potential management strategies. J Pharm Pract. 2005;18:258-277.
26. Vicriviroc maleate (SCH417690) [investigator's brochure]. Kenilworth, NJ; Schering-Plough; September 2006.
27. Isentress [package insert]. Whitehouse Station, NJ; Merck; October 2007.
28. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California. Abstract 143LB.
29. Goebel F, Yakovlev A, Pozniak AL, et al. Shortterm antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS. 2006;20:1721-1726.
30. Santoscoy M, Cahn P, Gonsalez C, et al. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204. Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUAB0103.
31. Krikorian SA, Rudorf DC. Drug-drug interactions and HIV therapy: What should pharmacists know? J Pharm Pract. 2005;18:278-294.
32. Abel S, Russell D, Ridgway C, et al. Overview of the drug-interaction data for maraviroc (UK-427, 857). Presented at: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Canada. Abstract 76.
33. Sansone A, Keung A, Tetteh E, et al. Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 582.
34. Sansone A, Saltzman M, Rosenberg M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. Presented at: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Canada. Abstract 79.
35. Iwamoto M, Wenning LA, Petry AA. Minimal effect of ritonavir and efavirenz on the pharmacokinetics of MK-0518. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract A-0373.
36. Ramanathan S, Skillington J, Plummer A, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (GS-9137/R) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract TUPE0080.
37. Mathias A, Hinkle J, Enejosa J, Pillero P, Kearney B. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and Tipranavir/r. Presented at: Fourth IAS Conference; July 22-25, 2007; Sydney, Australia. Abstract TuPDB06.
38. Piscitelli S, Baede P, Van't Klooster G, Graham N. TMC125 does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, CA. Abstract A1824.
39. Van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects. Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract TUPE0087.
40. Hardy H. Adherence to antiretroviral therapy: The emerging role of HIV pharmacotherapy specialists. J Pharm Pract. 2005;18:247-257.
41. Daar ES, Cohen C, Remien R, et al. Improving adherence to antiretroviral therapy. AIDS Read. 2003;13:81-90.
42. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. AIDS Read. 2000;10:177-185.
43. Vervoort S, Borleffs J, Hoepelman A, Grypdonk, MH. Adherence to antiretroviral therapy for HIV: A review of qualitative studies. AIDS. 2006;21:271-281.
44. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. F